Table 4.
Multiple regression analysis of SHASH (change in UACR)
| Variable | Estimate (β) | Standard error | t value | p value | Standardized β | VIF | Power |
|---|---|---|---|---|---|---|---|
| Intercept | −1.015 | 0.433 | −2.340 | 0.023 | 0.000 | | |
| Baseline eGFR | 0.021 | 0.006 | 3.180 | 0.003* | 0.350 | 1.140 | 0.876 |
| Baseline TG | −0.002 | 0.001 | −2.480 | 0.017* | −0.426 | 2.768 | 0.683 |
| SHASH [baseline UACR] | −0.387 | 0.118 | −3.270 | 0.002* | −0.361 | 1.147 | 0.894 |
| (eGFR_0w – 66.0269) × (SHASH [baseline UACR] − 0.01977) | 0.010 | 0.007 | 1.450 | 0.153 | 0.160 | 1.137 | |
| (TG_0w – 204.352) × (SHASH [baseline UACR] − 0.01977) | 0.000 | 0.001 | 0.470 | 0.642 | 0.081 | 2.787 | |
Change in UACR, the value obtained by subtracting the baseline UACR from the UACR at 24 weeks after spironolactone administration; VIF, variance inflation factor; SHASH, sinh-arcsinh normal distribution transformation; UACR, urine albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; TG, triglyceride.
*p < 0.05.